Natixis Investment Managers International Adaptimmune Therapeutics PLC Transaction History

Natixis Investment Managers International

  • $1.39 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019
SELL
$3.76 - $14.16 $238,226 - $897,149
-63,358 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$8.27 - $13.56 $348,324 - $571,133
-42,119 Reduced 39.93%
63,358 $859,000
Q2 2018

Aug 14, 2018
BUY
$10.42 - $13.74 $1.1 Million - $1.45 Million
105,477 New
105,477 $1.25 Million

Others Institutions Holding ADAP

# of Institutions
83
Shares Held
150M
Call Options Held
60.8K
Put Options Held
5.8K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $98M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Natixis Investment Managers International Portfolio

Follow Natixis Investment Managers International and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Investment Managers International, based on Form 13F filings with the SEC.

News

Stay updated on Natixis Investment Managers International with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email